Riot Platforms (RIOT) Competitors $9.44 +0.20 (+2.16%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends RIOT vs. VIVO, OSTK, OXFD, AWH, SOFI, ALLY, BSAC, WF, CIB, and OMFShould you be buying Riot Platforms stock or one of its competitors? The main competitors of Riot Platforms include Meridian Bioscience (VIVO), Overstock.com (OSTK), Oxford Immunotec Global (OXFD), Aspira Women's Health (AWH), SoFi Technologies (SOFI), Ally Financial (ALLY), Banco Santander-Chile (BSAC), Woori Financial Group (WF), Bancolombia (CIB), and OneMain (OMF). Riot Platforms vs. Meridian Bioscience Overstock.com Oxford Immunotec Global Aspira Women's Health SoFi Technologies Ally Financial Banco Santander-Chile Woori Financial Group Bancolombia OneMain Meridian Bioscience (NASDAQ:VIVO) and Riot Platforms (NASDAQ:RIOT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings. Does the MarketBeat Community favor VIVO or RIOT? Riot Platforms received 203 more outperform votes than Meridian Bioscience when rated by MarketBeat users. Likewise, 68.29% of users gave Riot Platforms an outperform vote while only 48.84% of users gave Meridian Bioscience an outperform vote. CompanyUnderperformOutperformMeridian BioscienceOutperform Votes31648.84% Underperform Votes33151.16% Riot PlatformsOutperform Votes51968.29% Underperform Votes24131.71% Do insiders and institutionals have more ownership in VIVO or RIOT? 89.7% of Meridian Bioscience shares are owned by institutional investors. Comparatively, 40.3% of Riot Platforms shares are owned by institutional investors. 2.3% of Meridian Bioscience shares are owned by insiders. Comparatively, 6.9% of Riot Platforms shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is VIVO or RIOT more profitable? Riot Platforms has a net margin of 115.35% compared to Meridian Bioscience's net margin of 12.70%. Meridian Bioscience's return on equity of 16.74% beat Riot Platforms' return on equity.Company Net Margins Return on Equity Return on Assets Meridian Bioscience12.70% 16.74% 13.09% Riot Platforms 115.35%15.59%14.66% Which has higher valuation & earnings, VIVO or RIOT? Meridian Bioscience has higher revenue and earnings than Riot Platforms. Riot Platforms is trading at a lower price-to-earnings ratio than Meridian Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMeridian Bioscience$333.02M4.49$42.46M$0.9735.02Riot Platforms$280.70M10.21-$49.47M$1.516.25 Which has more volatility & risk, VIVO or RIOT? Meridian Bioscience has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500. Comparatively, Riot Platforms has a beta of 4.1, meaning that its stock price is 310% more volatile than the S&P 500. Does the media favor VIVO or RIOT? In the previous week, Riot Platforms had 14 more articles in the media than Meridian Bioscience. MarketBeat recorded 14 mentions for Riot Platforms and 0 mentions for Meridian Bioscience. Meridian Bioscience's average media sentiment score of 0.00 beat Riot Platforms' score of -0.18 indicating that Meridian Bioscience is being referred to more favorably in the media. Company Overall Sentiment Meridian Bioscience Neutral Riot Platforms Neutral Do analysts recommend VIVO or RIOT? Riot Platforms has a consensus target price of $16.35, indicating a potential upside of 73.20%. Given Riot Platforms' higher possible upside, analysts plainly believe Riot Platforms is more favorable than Meridian Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Meridian Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ARiot Platforms 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 SummaryRiot Platforms beats Meridian Bioscience on 12 of the 18 factors compared between the two stocks. Ad Paradigm PressEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… Get Riot Platforms News Delivered to You Automatically Sign up to receive the latest news and ratings for RIOT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RIOT vs. The Competition Export to ExcelMetricRiot PlatformsNondepository credit institutions IndustryBusiness SectorNASDAQ ExchangeMarket Cap$2.87B$7.32B$6.56B$8.53BDividend YieldN/A5.17%2.62%4.14%P/E Ratio6.2518.4939.5915.18Price / Sales10.217.24214.9292.77Price / Cash10.6746.0024.8834.07Price / Book1.031.994.555.02Net Income-$49.47M$462.43M$114.67M$225.46M7 Day Performance-2.07%-2.00%-0.73%0.37%1 Month Performance30.21%2.36%-0.13%3.57%1 Year Performance-16.46%57.78%23.53%29.44% Riot Platforms Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RIOTRiot Platforms3.6429 of 5 stars$9.44+2.2%$16.35+73.2%-7.5%$2.87B$280.70M6.25340Analyst ForecastOptions VolumeAnalyst RevisionNews CoverageGap UpVIVOMeridian Bioscience1.1361 of 5 stars$33.97flatN/AN/A$1.50B$333.02M35.02702Analyst ForecastOSTKOverstock.comN/AN/AN/AN/A$760.30M$1.93B-4.671,050Analyst ForecastGap UpOXFDOxford Immunotec GlobalN/A$21.99flatN/AN/A$570.90M$73.71M-32.82273Analyst ForecastAWHAspira Women's Health1.1844 of 5 stars$0.92-2.1%$4.40+380.9%-80.8%$14.70M$8.92M-0.63110Analyst ForecastGap UpSOFISoFi Technologies2.2816 of 5 stars$11.22+7.2%$9.33-16.8%+45.6%$11.96B$2.32B-46.754,400Earnings ReportAnalyst ForecastAnalyst RevisionHigh Trading VolumeALLYAlly Financial4.991 of 5 stars$36.12+2.9%$40.38+11.8%+42.3%$10.98B$8.83B15.5711,100Short Interest ↓BSACBanco Santander-Chile4.0079 of 5 stars$19.69-0.7%$21.00+6.7%+10.4%$9.28B$2.31T14.929,229Short Interest ↑News CoverageWFWoori Financial Group4.0557 of 5 stars$34.39-2.0%N/A+26.0%$8.51B$17.78B4.41150CIBBancolombia2.8104 of 5 stars$32.43+4.0%$33.67+3.8%+23.5%$7.80B$27.84T5.1134,756OMFOneMain4.9273 of 5 stars$51.90+9.3%$54.00+4.0%+37.0%$6.22B$4.38B10.669,100Dividend AnnouncementAnalyst ForecastInsider SellingAnalyst RevisionNews CoverageHigh Trading Volume Related Companies and Tools Related Companies VIVO Alternatives OSTK Alternatives OXFD Alternatives AWH Alternatives SOFI Alternatives ALLY Alternatives BSAC Alternatives WF Alternatives CIB Alternatives OMF Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RIOT) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Riot Platforms, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Riot Platforms With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
